In the current AML setting, expeditious confirmation of IDH1/2 and FLT3 mutation status is particularly important, together with p53, core-binding factor, and myelodysplasia-related changes-associated cytogenetics, given the availability of targeted therapies that improve outcomes in patients with relevant molecular or cytogenetic features3. This evidence concerns the gene IDH1 and acute myeloid leukemia.